molecules of the month


BTK-selective covalent kinase inhibitor

Ph. I completed in HV, in Ph. II

SBDD from reversible BTK inhibitor and opt.

J. Med. Chem., Mar. 4, 2020

Novartis, Basel, CH

Structure of BTK inhibitor Remibrutinib
1 min read

Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: